Therapeutic Potential of PGG in the Clearance of Established Cardiac Amyloid Deposits

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  iScience https://doi.org/10.1016/j.isci.2025.114170 
Dr. Asuka Kagami  et al.

Points

Researchers screened over fifteen hundred plant extracts to identify a specific pomegranate-derived molecule that acts as a potent disruptor of pre-formed transthyretin amyloid fibrils in clinical models.
The compound successfully disaggregated both wild-type and mutant protein deposits which are responsible for systemic organ dysfunction while showing high molecular specificity by sparing other common amyloid proteins.
Treatment with this polyphenolic molecule in nematode models led to a significant reduction in protein aggregation and a measurable extension of both the lifespan and healthspan of the organisms.
Chemical analysis revealed that the multiple galloyl groups attached to the glucose core are structurally essential for the compound to effectively interact with and destabilize insoluble amyloid fibrils.
Ex vivo experiments confirmed that the molecule can disrupt amyloid fibrils isolated directly from human cardiac tissue, highlighting its potential as a next-generation therapy for clearing pathogenic protein deposits.

Summary

This research evaluated the efficacy of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose as a novel amyloid disruptor for the treatment of transthyretin amyloidosis. While current standard of care therapies focus on tetramer stabilization or the suppression of protein production, they demonstrate limited efficacy against established insoluble amyloid deposits. To address this therapeutic gap, investigators screened 1,509 plant extracts, identifying this polyphenol derived from pomegranate leaves and branches as a potent agent capable of disaggregating pre-formed fibrils in both mutant V30M and wild-type variants.

Experimental data demonstrated high molecular specificity, as the compound successfully disassembled transthyretin aggregates without affecting amyloid-beta fibrils associated with Alzheimers disease. In a nematode model expressing human protein fragments, treatment significantly reduced deposits and extended both the lifespan and healthspan of the organisms. Furthermore, structural analysis confirmed that multiple galloyl groups attached to the glucose core are essential for bioactivity, facilitating the direct interaction required to destabilize the thermodynamic stability of the amyloid fibrils.

Clinical relevance was reinforced through ex vivo testing, where the compound effectively disrupted amyloid fibrils isolated from the cardiac tissue of a patient with hereditary transthyretin amyloidosis. These results suggest that glycosidic scaffolds bearing galloyl moieties represent a promising lead for next-generation amyloid-clearing agents. By actively removing pathogenic deposits rather than merely slowing their formation, these compounds could address a major unmet need in the clinical management of systemic organ dysfunction caused by protein misfolding.

Link to the article: https://www.cell.com/iscience/fulltext/S2589-0042(25)02431-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2589004225024319%3Fshowall%3Dtrue

References

Kagami, A., Hashimoto, N., Sasaki, R., Fukushima, Y., Devkota, H. P., Tanaka, S., Wada, M., Yamanaka, K., Yamakawa, S., Misumi, S., Yokoyama, T., Mizuguchi, M., Sato, T., Nakamura, T., Kotani, S., Suico, M. A., Kai, H., Ueda, M., & Shuto, T. (2026). Glycosidic scaffold bearing multiple galloyl moieties from pomegranate disrupts transthyretin amyloids. iScience, 29(1), 114170. https://doi.org/10.1016/j.isci.2025.114170